Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys

Retrovirology

Volumn 8, Issue , 2011, Pages

  Mußil, Bianka ^a,c   Sauermann, Ulrike ^a   Motzkus, Dirk ^a   Stahl Hennig, Christiane ^a   Sopper, Sieghart ^a,b  

^a GERMAN PRIMATE CENTER   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; CYTIDINE DEAMINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; ANIMAL; CELL SURVIVAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA MULATTA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; UPREGULATION; VIROLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; CELL SURVIVAL; CYTIDINE DEAMINASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; UP-REGULATION; VIRAL LOAD;

EID: 80053341099     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-77     Document Type: Article

References (74)

1. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. Aids 1994, 8:1123-1128. 10.1097/00002030-199408000-00014, 7986410.
2. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004, 4:868-877. 10.1038/nri1489, 15516966.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103. 10.1038/nature01709, 12808466.
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650. 10.1038/nature00939, 12167863.
5. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004, 14:1385-1391. 10.1016/j.cub.2004.06.050, 15296757.
6. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98. 10.1038/nature01707, 1350966, 12808465.
7. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9:1398-1403. 10.1038/nm946, 14528301.
8. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-1407. 10.1038/nm945, 14528300.
9. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060. 10.1126/science.1089591, 14564014.
10. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007, 282:2587-2595.
11. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005, 15:166-170. 10.1016/j.cub.2004.12.068, 15668174.
12. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006, 80:9259-9269. 10.1128/JVI.00888-06, 1563905, 16940537.
13. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, Ohmichi M, Ito M, Takaori-Kondo A, Koyanagi Y. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol 2010, 84:9546-9556. 10.1128/JVI.00823-10, 2937654, 20610708.
14. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 279:7792-7798.
15. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006, 80:7645-7657. 10.1128/JVI.00206-06, 1563726, 16840343.
16. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, Munson PJ, Wahl SM. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 2007, 110:393-400. 10.1182/blood-2006-10-051763, 1896122, 17371941.
17. Pido-Lopez J, Whittall T, Wang Y, Bergmeier LA, Babaahmady K, Singh M, Lehner T. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol 2007, 178:1671-1679.
18. Rose KM, Marin M, Kozak SL, Kabat D. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem 2004, 279:41744-41749. 10.1074/jbc.M406760200, 15297452.
19. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 2007, 282:3539-3546.
20. Lafferty MK, Sun L, DeMasi L, Lu W, Garzino-Demo A. CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood 2010, 115:1564-1571. 10.1182/blood-2009-06-226423, 2830761, 20023216.
21. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010, 38:4274-4284. 10.1093/nar/gkq174, 2910054, 20308164.
22. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 2010, 107:9843-9848. 10.1073/pnas.0911932107, 2906837, 20457926.
23. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O'Brien SJ, Telenti A, Winkler CA. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004, 78:11070-11076. 10.1128/JVI.78.20.11070-11076.2004, 521814, 15452227.
24. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009, 5:e1000414. 10.1371/journal.ppat.1000414, 2671846, 19424423.
25. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, Kanki PJ. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis 2008, 198:486-492. 10.1086/590212, 18598197.
26. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009, 6:23. 10.1186/1742-4690-6-23, 2661038, 19254362.
27. Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol 2006, 80:2069-2072. 10.1128/JVI.80.4.2069-2072.2006, 1367163, 16439564.
28. Desrosiers RC. Non-human primate models for AIDS vaccines. Aids 1995, 9(Suppl A):S137-141.
29. Joag SV. Primate models of AIDS. Microbes Infect 2000, 2:223-229. 10.1016/S1286-4579(00)00266-5, 10742694.
30. Dittmer U, Hunsmann G. Long-term non-progressive human immunodeficiency virus infection: new insights from the simian immunodeficiency virus model. J Gen Virol 1997, 78(Pt 5):979-984.
31. King NW, Chalifoux LV, Ringler DJ, Wyand MS, Sehgal PK, Daniel MD, Letvin NL, Desrosiers RC, Blake BJ, Hunt RD. Comparative biology of natural and experimental SIVmac infection in macaque monkeys: a review. J Med Primatol 1990, 19:109-118.
32. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 2004, 279:53379-53386. 10.1074/jbc.M408802200, 15466872.
33. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31. 10.1016/S0092-8674(03)00515-4, 12859895.
34. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170. 10.1126/science.272.5265.1167, 8638160.
35. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Munoz A. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. Jama 2007, 297:2349-2350. 10.1001/jama.297.21.2349, 17551128.
36. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, Johnson PR, Hu SL, Haigwood NL. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 1997, 71:284-290. 191049, 8985348.
37. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006, 203:41-46. 10.1084/jem.20051512, 2118075, 16418394.
38. Holterman L, Niphuis H, Koornstra W, Dubbes R, ten Haaft P, Heeney JL. The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. J Gen Virol 2000, 81:1719-1726.
39. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004, 14:1392-1396. 10.1016/j.cub.2004.06.057, 15296758.
40. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809. 10.1016/S0092-8674(03)00423-9, 12809610.
41. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004, 78:6073-6076. 10.1128/JVI.78.11.6073-6076.2004, 415831, 15141007.
42. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008, 321:1343-1346. 10.1126/science.1161121, 2701658, 18772436.
43. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol 2008, 82:10998-11008. 10.1128/JVI.01311-08, 2573259, 18786991.
44. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, Naddeo V, Lopalco L, Clivio A, Cesana E, Fasano F, Bergamaschi C, Mazzotta F, Miyazawa M, Clerici M. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007, 195:960-964. 10.1086/511988, 17330785.
45. Jin X, Wu H, Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 2007, 4:20. 10.1186/1742-4690-4-20, 1832211, 17374143.
46. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005, 79:11513-11516. 10.1128/JVI.79.17.11513-11516.2005, 1193574, 16103203.
47. Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, Ndung'u T. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24:195-204.
48. Rosenberg YJ, Zack PM, White BD, Papermaster SF, Elkins WR, Eddy GA, Lewis MG. Decline in the CD4+ lymphocyte population in the blood of SIV-infected macaques is not reflected in lymph nodes. AIDS Res Hum Retroviruses 1993, 9:639-646. 10.1089/aid.1993.9.639, 8103665.
49. Rosok BI, Bostad L, Voltersvik P, Bjerknes R, Olofsson J, Asjo B, Brinchmann JE. Reduced CD4 cell counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV-1 infection. Aids 1996, 10:F35-38.
50. Halbach A, Nierwetberg D, Muller JG, Sauer U, Kerkau T, Stolte N, Hofmann P, Czub S, ter Meulen V, Sopper S. Total numbers of lymphocyte subsets in different lymph node regions of uninfected and SIV-infected macaques. J Med Primatol 2000, 29:148-157.
51. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009, 83:9474-9485. 10.1128/JVI.01089-09, 2738220, 19587057.
52. Vetter ML, Johnson ME, Antons AK, Unutmaz D, D'Aquila RT. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog 2009, 5:e1000292. 10.1371/journal.ppat.1000292, 2631133, 19197360.
53. Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, Yamada A. High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol 2006, 37:327-332. 10.1007/s10735-006-9059-0, 17036163.
54. Taylor MW, Grosse WM, Schaley JE, Sanda C, Wu X, Chien SC, Smith F, Wu TG, Stephens M, Ferris MW, McClintick JN, Jerome RE, Edenberg HJ. Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res 2004, 24:107-118. 10.1089/107999004322813354, 14980075.
55. Ying S, Zhang X, Sarkis PT, Xu R, Yu X. Cell-specific regulation of APOBEC3F by interferons. Acta Biochim Biophys Sin (Shanghai) 2007, 39:297-304.
56. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self S, Borrow P. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733. 10.1128/JVI.01844-08, 2663284, 19176632.
57. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ. The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J Virol 2002, 76:8433-8445. 10.1128/JVI.76.16.8433-8445.2002, 155165, 12134046.
58. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555. 2786805, 19959873.
59. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789. 10.1182/blood-2005-12-4818, 1895811, 16467198.
60. Clerici M, Balotta C, Meroni L, Ferrario E, Riva C, Trabattoni D, Ridolfo A, Villa M, Shearer GM, Moroni M, Galli M. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res Hum Retroviruses 1996, 12:1053-1061. 10.1089/aid.1996.12.1053, 8827221.
61. Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT, Connors M. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 2007, 81:2713-2725. 10.1128/JVI.01830-06, 1865970, 17182676.
62. Amicosante M, Poccia F, Gioia C, Montesano C, Topino S, Martini F, Narciso P, Pucillo LP, D'Offizi G. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003, 188:661-665. 10.1086/377454, 12934181.
63. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, Patterson S. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001, 98:2574-2576. 10.1182/blood.V98.8.2574, 11588058.
64. Lore K, Sonnerborg A, Brostrom C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, van Kooyk Y, Andersson J. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. Aids 2002, 16:683-692. 10.1097/00002030-200203290-00003, 11964524.
65. Wang Y, Bergmeier LA, Stebbings R, Seidl T, Whittall T, Singh M, Berry N, Almond N, Lehner T. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 2009, 27:870-881. 10.1016/j.vaccine.2008.11.084, 2744409, 19084567.
66. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, Shearer GM. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995, 96:867-876. 10.1172/JCI118133, 185273, 7635981.
67. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J, Njagi E, Mwangi F, Rostron T, Onyango J, Oyugi J, MacDonald KS, Bwayo JJ, Plummer FA. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001, 79:3-13. 10.1016/S0165-2478(01)00260-7, 11595284.
68. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 2008, 82:8172-8182. 10.1128/JVI.01115-08, 2519552, 18550667.
69. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005, 435:108-114. 10.1038/nature03493, 15829920.
70. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers R. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 1990, 248:1109-1112. 10.1126/science.2160735, 2160735.
71. Stahl-Hennig C, Voss G, Dittmer U, Coulibaly C, Petry H, Makoschey B, Cranage MP, Aubertin AM, Luke W, Hunsmann G. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. Aids 1993, 7:787-795. 10.1097/00002030-199306000-00005, 8363756.
72. Abel K, Alegria-Hartman MJ, Zanotto K, McChesney MB, Marthas ML, Miller CJ. Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine 2001, 16:191-204. 10.1006/cyto.2001.0961, 11814315.
73. Rodriguez-Jimenez FJ, Krause A, Schulz S, Forssmann WG, Conejo-Garcia JR, Schreeb R, Motzkus D. Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics 2003, 81:175-183. 10.1016/S0888-7543(02)00034-4, 12620395.
74. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Boros S, Liljestrom P, Norley S, Heeney J, Titti F. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004, 85:1191-1201. 10.1099/vir.0.79794-0, 15105535.